ER Staining in Breast Cancer
ER testing by immunohistochemistry (IHC) is the standard method to determine which breast cancer patients will benefit from endocrine therapy, with tumors showing ≥1% nuclear staining classified as ER-positive and eligible for hormonal treatment 1.
Clinical Significance and Treatment Impact
ER status is fundamentally a predictive biomarker rather than primarily prognostic—it identifies patients who will respond to endocrine therapies like tamoxifen, aromatase inhibitors, or fulvestrant 1, 2. Approximately 79-84% of breast cancers are ER-positive, with higher rates in postmenopausal women 1.
Current Classification Thresholds
The 2020 ASCO/CAP guidelines establish clear cutoffs 1:
- ER-Positive: ≥1% tumor cell nuclei staining
- ER-Negative: 0% tumor cell nuclei staining
- ER Low Positive (new category): 1-10% staining—requires special reporting with comment noting limited evidence for endocrine therapy benefit
Critical Nuances About ER Expression Levels
The Low ER Problem (1-10% Staining)
Tumors with 1-10% ER staining behave clinically like ER-negative cancers despite technically being "positive" 3. These cancers:
- Show better response to chemotherapy than ER >10% tumors (similar to ER-negative) 3
- Have significantly worse disease-free and overall survival compared to ER >10% tumors 3
- May represent technical staining artifacts rather than true low expression—studies show these cases often have decreased dynamic range in normal adjacent tissue, suggesting poor assay performance 4
Clinical Action: Consider treating ER 1-10% cases more like triple-negative breast cancer with chemotherapy rather than relying on endocrine therapy alone 3.
Intermediate ER Expression (10-90% Staining)
Recent evidence reveals that ER expression around 45-50% represents a prognostic inflection point 5:
- Recurrence risk peaks around 45% ER positivity then decreases
- Tumors with ER <50% show molecular features similar to triple-negative disease, including proliferative pathways and p53 signaling 5
- For neoadjuvant chemotherapy, 14% ER expression distinguishes chemosensitivity likelihood 5
Technical Requirements for Accurate Testing
Pre-analytical Factors
Tissue fixation is critical: Requires 6-8 hours minimum in formalin (but <48 hours) for optimal ER detection 1, 6. Inadequate fixation causes false-negative results.
Quality Control Mandates
The guidelines require 1:
- Laboratory-specific standard operating procedures for cases with 0-10% staining
- Control status must be reported for all cases with 0-10% staining
- Internal positive controls should show moderate to strong staining—weak or negative internal controls invalidate the assay 7
Common Pitfall: Negative ER results should never be reported when internal positive controls are weak or negative, as this indicates assay failure 7.
Antibody Selection
Newer antibodies like SP1 clone may identify additional patients who benefit from hormonal therapy compared to older antibodies 1.
Treatment Decision Algorithm
For ER ≥50% or ER >10% with strong staining:
- Endocrine therapy is standard (tamoxifen, aromatase inhibitors, or fulvestrant) 2, 8
- Consider genomic assays (Oncotype DX, EndoPredict) for node-negative disease to guide chemotherapy decisions 2
For ER 10-50% (intermediate):
- Endocrine therapy indicated but consider adding chemotherapy
- Higher chemosensitivity expected compared to ER >50% 5
- Genomic testing particularly valuable in this range
For ER 1-10% (low positive):
- Treat as ER-negative: prioritize chemotherapy over endocrine therapy 3
- Verify result with repeat testing if clinically discordant 1
- Check internal controls to rule out technical failure 4, 7
For ER 0% (negative):
- Confirm adequate fixation and control performance 1
- No endocrine therapy benefit expected
- Consider triple-negative treatment protocols
Resistance and Combination Strategies
ESR1 mutations are a common resistance mechanism to SERMs and aromatase inhibitors 9. When endocrine resistance develops, options include:
- Fulvestrant (SERD) with demonstrated activity post-tamoxifen 9, 8
- CDK4/6 inhibitors combined with endocrine therapy for advanced disease 8
- Emerging oral SERDs, PROTACs, and SERCAs in development 9
Reporting Requirements
For ER testing, pathology reports must include 1:
- Percentage of tumor cells with nuclear staining
- Intensity of staining
- Control status (especially for 0-10% results)
- For 1-10% results: use "ER Low Positive" designation with comment about limited endocrine therapy benefit data